Search PubMed⌕ Search

Biomedical subjects

U Fuhrmann

Publications and source records attributed to U Fuhrmann.

32 records · Page 2Linked to original sources

[HBs-antigen determination during pregnancy with reference to prevention of a postnatal infection in the newborn infant].

In 1980 and 1981 the blood samples of 2040 pregnant women from the Department of Obstetrics of the University Hospital of Cologne have been examined for HBs-antigen. In 37 samples (1.8%) HBs-antigen was detected. As there are considerable racial as well as geographic differences in the frequency of HBs-antigenemia, we differentiated between German and foreign women. In 10 out of 1519 (0.7%) German and in 27 out of 521 (5.2%) foreign women, respectively, HBs-antigen could be demonstrated. Only 1 woman was known to be HBs-antigen positive. Until now, 38 children have been born in the University Hospital to 33 HBs-antigen-positive mothers. After birth, 35 children received hepatitis B immune globulin (HBIG). So far, none of these immunised children exhibited signs of a hepatitis B infection--22 children have been followed up 5-19 months, and 13 children 1-4 months. Three newborns did not receive HBIG: One child was already infected at time of birth, the 2 other children were erroneously not given HBIG. One of these 2 children fell ill at the age of 5 months with clinical and serological manifestations of hepatitis B, the other child appears healthy up to date (11 weeks).

Ethnicity↗

[Nephroblastoma].

Explore the source record for details and available documents.

Bone Neoplasms↗

[Nephroblastoma, partly appearing as a sarcoma botryoides of the renal pelvis (author's transl)].

A renal tumour in a 4-year old girl morphologically appeared as both a nephroblastoma and, in parts, as a sarcoma botryoides of the renal pelvis. The histogenesis of this dysontogenetic tumour is most probably due to a disturbance of growth and differentiation both of the metanephrogenic blastema as well as partly of the urethral bud. This type of dysontogenetic tumour is extremely rare. Problems of diagnosis and operative therapy and the possibility of postoperative radiation therapy and cystostatic treatment are discussed.

Child, Preschool↗

[Cardiotoxicity in long term treatment with cytostatics (author's transl)].

During cytostatic combination treatment with five different anti-tumor agents two female patients suffered from cardiac failure which proved fatal. This was mainly due to doxorubicine (adriamycin) and daunorubicine. In an 8-year-old patient the cumulative dose was reached after 14 months of treatment (total dose of adriamycin 420 mg/m2, of daunorubicine 280 mg/m2) and in a 7-year-old patient after 16 months (total dose of adriamycin 480 mg/m2, of daunorubicine 280 mg/m2). Cardiac failure which occurred 12 months after the onset of treatment in a 12-year-old girl (total dose of adriamycin 310 mg/m2 and of daunorubicine 280 mg/m2) could be brought under control. The cumulative dose of adriamycin should be limited to 500 mg/m2 in children without risk factors.

Bone Neoplasms↗

Novel mannosidase inhibitor blocking conversion of high mannose to complex oligosaccharides.

Many secretory and membrane proteins are glycoproteins carrying asparagine-linked (N-linked) oligosaccharides. There are two types of N-linked glycans, referred to as high-mannose and complex type, respectively. Biosynthesis of N-linked glycans of the complex type proceeds via a high-mannose intermediate. After the initial transfer of a high-mannose oligosaccharide with the composition (Glc)3(Man)9(GlcNAc)2 from a lipid carrier to the nascent polypeptide chain, trimming reactions take place. Trimming glucosidases remove the glucose residues quantitatively and mannosidases IA/B and II can remove all but three mannose residues. After trimming, terminal sugars such as N-acetylglucosamine, galactose, sialic acid and fucose may be added and result in the conversion to a glycan of the complex type. Because suitable inhibitors were lacking, it was difficult to assess the importance of the trimming reactions for proper intracellular traffic, modification reactions other than the addition of terminal sugars, or as regulatory steps in glycoprotein processing. Here we describe the action of 1-deoxymannojirimycin (1,5-dideoxy-1,5-imino-D-mannitol, dMM; Fig. 1) on the biosynthesis of IgM and IgD. dMM is the mannose analogue of 1-deoxynojirimycin (dNM; Fig. 1), itself a glucosidase inhibitor. We present evidence that dMM is a mannosidase inhibitor. In vivo dMM inhibits the equivalent of the mannosidase IA/B activities and blocks conversion of high-mannose to complex oligosaccharides. It is the first such inhibitor to be reported. Interference with the biosynthetic pathway of N-linked glycans could prove to be a powerful way to manipulate carbohydrate structure in vivo.

1-Deoxynojirimycin↗

[Efficiency and side effects of antiretroviral treatment of HIV infected pregnant women].

OBJECTIVE: Antiretroviral treatment (ART) of pregnant women and newborn reduces the vertical HIV transmission below 2 % but long term effects are still not clear. METHOD: We analyzed the data of 59 children born to HIV infected women. RESULTS: The median observation time was 404 (14-740) days. There was no vertical HIV transmission (95 %-confidence interval [CI] 0-5.1 %). Among 6 children without prenatal ART one child with congenital diaphragmatic hernia was born. In 53 infants with prenatal ART we observed 19 congenital malformations (35.8 %, 95 %-CI 23.2-50.6 %). Three were severe malformations (5.7 %, 95 %-CI 1.2-15.5 %): one supraorbital hemangioma (after zidovudine), one athetoid cerebral palsy without evidence of mitochondrial dysfunction (after zidovudine), and one unilateral femoral hypoplasia (after short term zidovudine, lamivudine, and efavirenz in late pregnancy). Sixteen minor malformations were found (30.1 %, 95 %-CI 21.2-43.8 %): ventricular septal defect (closed spontaneously after 6 months), atrial septal defect, transient and persistent pulmonary stenoses, hexadactylies, unilateral hearing impairment, dystopic kidney, subependymal bleeding cysts, and mild dilation of ventricles. CONCLUSIONS: ART prevents vertical HIV transmission. All women should be advised ART during pregnancy and delivery. The prevalence of malformations after prenatal/perinatal ART appears considerably high. Therefore, detailed information for the parents and long term follow-up of all children exposed to antiretroviral drugs are crucial.

Anti-HIV Agents↗

Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.

Antiprogestins can modulate oestrogenic effects in various oestrogen-dependent tissues, dependent on species, tissue, dose and duration of treatment. Enhanced oestrogenic responses to mifepristone and onapristone occur in vitro and in vivo. However, the antiprogestins mifepristone, onapristone, and ZK 137 316 can block the ability of oestradiol to increase endometrial growth in non-human primates. Our purposes were firstly, to decide whether mifepristone and onapristone had direct oestrogenic activity in vitro and in the uterus of spayed and immature rats, and secondly, to discover whether antiprogestins exhibit inhibitory effects on oestrogen action in the uterus in spayed, oestrogen-substituted rats. In transactivation assays, mifepristone induced oestrogenic response, whereas onapristone had only marginal effects on reporter gene transcription. In immature rats, onapristone and mifepristone markedly increased uterine weights, and onapristone, but not mifepristone significantly enhanced endometrial luminal epithelial height, a sensitive oestrogen parameter. Conversely, in spayed and adrenalectomized rats, neither onapristone nor mifepristone changed uterine weights or endometrial morphology, indicating that their effects in immature rats were indirect. In spayed, oestrogen-substituted rats, antiprogestins did not block oestradiol-stimulated endometrial growth and luminal and glandular epithelium were stimulated more after antiprogestin plus oestrogen, than after oestradiol alone. All compounds induced compaction of the uterine stroma. In spayed rats, onapristone and some other 13alpha-configured (type 1) antagonists (ZK 135 569, ZK 131 535) reduced oestradiol-stimulated myometrial proliferation and induced an overall uterine weight reduction in animals treated with oestrogen and antiprogestins, in comparison with oestradiol-treated controls. 13beta- configured (type II) antagonists, including mifepristone, lilopristone and ZK 112 993, were not effective. In the uteri of spayed rats, onapristone was also found to enhance the oestradiol-stimulatory effect on expression of the oestrogen-dependent proto-oncogene, c-fos. In conclusion, antiprogestins do not inhibit, but rather enhance, oestrogen-induced uterine glandular and luminal epithelium in spayed rats, contrary to their effects in primates. The rat model is unsuitable to study endometrial antiproliferative effects of antiprogestins in primate uteri.

Animals↗